Biocracked
Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
Research

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

Dr. Synapse · · 8 min read

Allurar CBL-514 Lipolysis: Binciken Mataki na 2

CBL‑514 wani allura ne da ake bincike wanda aka ƙera don haifar da apoptosis na sel ɗin kitse (adipocytes) a cikin ciki. Gwajin mataki na 2 da aka wallafa a Aesthetic Surgery Journal a 2025 ya haɗa da mahalarta 76 da aka raba ta bazuwar. An samu raguwar ƙimar kitse da aka auna ta hanyar ultrasound idan aka kwatanta da maganin saline, yayin da matsakaicin nauyin jiki ba ya sauyawa. Sakamakon na da sha'awa, amma ƙirar gwajin na da wasu manyan iyakoki. Wannan ƙididdiga na nuni da abin da gwajin ya tabbatar, abin da ba ya tabbatar, da wuraren da ake buƙatar ƙarin bincike.

Ba shawarar kiwon lafiya ba. CBL‑514 yana cikin bincike kuma ana ba shi ne daga masu binciken gwaji, ba a kan mutum kai tsaye ba.

Menene CBL‑514 (da abin da ba shi ba)

Sunan da ya dace shi ne CBL‑514; a kan yi kuskuren rubuta CL‑514. Allurar na fitowa daga kamfanin Caliway Biopharmaceuticals da ke New Taipei City, Taiwan. Ana gabatar da ita a matsayin allurar subcutaneous wadda ake yi a yankin da ake magancewa – a wannan gwajin, a cikin ciki. Ba maganin kari ba ne, ba kwayar baki ba, kuma ba samfurin da aka amince da shi don amfani ga jama'a ba. A lokacin da aka wallafa takardar, FDA ba ta amince da wannan samfur ba. Kayan da FDA ta amince da shi don rage kitse shi ne ATX‑101 (deoxycholic acid, Kybella), wanda ake amfani da shi ne kawai a yankin ƙasa da ƙirji (submental).

Takardar ba ta bayyana cikakken tsarin sinadaran ba, don haka babu jerin abubuwan da za a tantance.

Mafi muhimmancin tushen shine Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC. Aesthet Surg J. 2025;45(6):611‑620 (doi:10.1093/asj/sjaf032; ClinicalTrials.gov NCT04897412). An buɗe shi a: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080885/.

Hanyar aikin: rahoton kamfani, ba na mutane ba

Takardar mataki na 2a da ta gabata (Goodman et al., 2022) ƙarama ce kuma a buɗe‑label, ba tare da ƙungiyar placebo ba. Ta nuna cewa CBL‑514 yana hana kinase ɗin sel DYRK1b, yana ƙara aikin caspase‑3 da Bax/Bcl‑2, kuma yana haifar da apoptosis na adipocytes. Waɗannan hujjojin sun samo asali ne daga rahotannin sirri na Caliway da ba a wallafa ba.

Saboda haka, wannan hanya ta samo asali ne daga gwajin ba‑na‑mutane na kamfanin, ba a tabbatar da ita a cikin mutane ba a wannan gwaji. Hakanan ta bayyana mutuwar sel ɗin kitse a wuri, ba haɓakar tsarin metabolism ba, ba ƙone ƙalori ba, kuma ba raguwar nauyin jiki gaba ɗaya ba. Kiran “fat‑burning” daga masu tallata ƙwayoyin haɓaka jiki ba shi da tushe a nan.

Yadda aka gina gwajin mataki na 2

  • Tsari: gwaji mai bazuwar, single‑blind, parallel‑group, da placebo‑controlled, an gudanar da shi daga Fabrairu 2022 zuwa Maris 2023 a cibiyoyi 5 a Amurka da Australia.
  • Rarrabawa: an raba mahalarta a ratio na 2:1 tsakanin CBL‑514 da placebo (normal saline).
  • Blind: an toshe gani ga mahalarta kawai, an yi amfani da shinge na gani. Masu bincike, ma’aikatan cibiyar, mai tallafa, da mai lura da lafiyar su, duk sun san wane magani aka ba kowane mahalarta. Ba double‑blind ba ne.
  • Rawa: Caliway ta shiga cikin ƙirar gwajin, tattara bayanai, nazari da fassara, rubuta takarda, da kuma yanke shawarar gabatar da sakamakon.
  • Sharuɗɗan cancanta: shekaru 18‑64, BMI tsakanin 18.5‑35, nauyin aƙalla 50 kg, zurfin fata a cikin ciki tsakanin 3‑8 cm, da lafiyar hanta, koda, zuciya da garkuwar jiki.
  • Ka’ida ta daidaita nauyi: bambanci na kilogram 3 ko fiye daga farawa na haifar da dakatar da mahalarta.

Kima da jadawalin da aka yi amfani da su a gwajin

Kima da aka yi amfani da ita ita ce 2 mg/cm², wanda ke nufin har zuwa 600 mg a kowanne magani. Kowanne magani ya ƙunshi allurai 25‑50, bisa ga shawarar mai bincike, an ɗora su a tazara 2.45 cm. Kowanne allura ya ƙunshi 2.4 mL na CBL‑514 ko adadin daidai na saline. Mahalarta sun karɓi har zuwa magani huɗu a tazara makonni huɗu, sannan an bi su a makonni 4 da 8 bayan maganin ƙarshe. Wannan tsari na gwaji ne, ba don amfani kai ba.

Yadda aka auna kitse

An auna kitse ta hanyar ultrasound a wurare huɗu (4 cm da 10 cm daga dama da hagu na ma’aunin ciki). An ɗauki hotuna uku a kowane wuri, an yi matsakaici, kuma ƙwararrun masu yin ultrasound ne suka gudanar da aikin. An ƙididdige ƙimar ta hanyar ƙirga kubu: yanki 300 cm² da aka tantance a matsayin wurin magani an ninka da matsakaicin kaurin kitse. Masu bincike sun kuma yi amfani da hoton 3D. Babban manufa ita ce tantance adadin mahalarta da suka rasa aƙalla 150 mL a makonni 4 da 8 na bibiyar.

Sakamakon da aka samu

An tantance mutane 130, an shiga 81, daga ciki aka bazuwar 76 (CBL‑514 = 50, placebo = 26). An magance 75 (CBL‑514 = 49, placebo = 26). Daga cikin waɗannan 75, 38 suka kammala gwajin, 37 ba su kammala ba, wanda ke nuni da kaso na 49.3 % na rashin kammala. Dalilan sun haɗa da rasa bibiyar (6), janye kai (7), rashin daidaita nauyi (7), rashin iya bin jadawalin (6), da kuma mummunan sakamako (4).

Yawan mahalarta a ƙa'ida ta ITT (intention‑to‑treat) shi ne 76, yayin da a ƙa'ida ta PP (per‑protocol) kawai 30 ne.

Rukuni na CBL‑514 (n = 50) ya ƙunshi mata 94 % da fararen fata 86 %, matsakaicin shekaru 46.3, da matsakaicin BMI 27.77. Rukuni na placebo ya ƙunshi mata 80.8 %. Wannan ya nuna cewa gwajin ya fi mayar da hankali kan mata masu nauyi matsakaici da kitse a cikin ciki.

Sakamakon tasiri da ƙananan lambobi

Masu bincike sun bayyana cewa gwajin ya cika babban manufa da dukkan manufa na biyu. Ƙananan lambobi suna raguwa a bibiyar saboda rashin halartar wasu mahalarta; don haka ya kamata a yi la’akari da wannan lokacin karanta sakamako.

Aƙalla 150 mL an rasa (ITT):

  • Makonni 4: CBL‑514 63.9 % (23/36; 95 % CI 46.22‑79.18) vs placebo 17.4 % (4/23; 95 % CI 4.95‑38.78); P < .001.
  • Makonni 8: CBL‑514 69.6 % (16/23; 95 % CI 47.08‑86.79) vs placebo 0.0 % (0/16); P < .001.

Aƙalla 200 mL an rasa (ITT):

  • Makonni 4: CBL‑514 58.3 % (21/36; 95 % CI 40.76‑74.49) vs placebo 8.7 % (2/23; 95 % CI 1.07‑28.04); P < .001.
  • Makonni 8: CBL‑514 60.9 % (14/23; 95 % CI 38.54‑80.29) vs placebo 0.0 % (0/16); P < .001.

Bincike na ƙari aƙalla 250 mL: 44.4 % (16/36) a makonni 4 da 52.2 % (12/23) a makonni 8 a rukunin CBL‑514. Babu ɗaya daga cikin placebo da ya kai wannan.

Canjin matsakaici (ITT, least‑squares): bambanci tsakanin rukuni ya kasance −206.62 mL a makonni 4 (95 % CI −276.09 zuwa −137.16) da −216.28 mL a makonni 8 (95 % CI −288.28 zuwa −144.28), duka P < .001.

Rukuni PP (mutane 30 kawai): bambanci tsakanin rukuni ya kasance −312.08 mL a makonni 4 da −276.83 mL a makonni 8. Wannan ƙungiyar tana da matuƙar tacewa, don haka za ta iya nuna sakamako mafi kyau fiye da ITT.

Magunguna da ake buƙata: Daga cikin mahalarta CBL‑514 28 da suka kai aƙalla 150 mL, 12 sun cimma bayan magani 1, 10 bayan magani 2. Wannan na nufin 22 cikin 28 (kimanin 79 %) sun samu sakamako bayan magani 1 ko 2. Mafi girman raguwar da aka rubuta shine fiye da 750 mL a cikin mahalarta guda ɗaya.

Nauyi bai canza ba, kuma wannan shi ne ainihin batu

Matsakaicin nauyin jiki ya tsaya ba tare da canji ba. Mahalarta na CBL‑514 sun nuna ƙaruwa na +0.45 kg a makonni 4 da +0.02 kg a makonni 8, yayin da rukunin placebo ya rage −0.76 kg da −0.26 kg. Takardar ta ba da rahoton raguwar kitse a wuri ko da a cikin wasu mahalarta da suka ƙara fiye da 1 kg (babu cikakken bayani). Wannan na nuni da tasirin kitse a wuri, amma yana nuna cewa ƙimar nauyi ba ta da amfani wajen auna amfanin. Babu shaidar ƙona kitse a duk jiki.

Tsaron lafiya da iyakoki: karanta kafin ka karanta manyan labarai

Tsaron lafiya ya haɗa da rikodin abubuwan da suka faru bayan magani, gwaje‑gwajen dakin gwaje‑gwaje, sigogi, ECG, duba jiki, da kuma sakamako a wurin allura. Mahalarta huɗu sun janye saboda mummunan sakamako. Wannan takarda ba ta bayar da cikakken rarrabuwa na mummunan sakamako ba, don haka ya kamata a duba sashen tsaron lafiya da kyau.

Mahimman ƙuntatawa:

  • Single‑blind kawai. Masu bincike da mai tallafa sun san wanene ya karɓi maganin.
  • Haɗin gwiwar mai tallafa a duk ƙirar, nazari da wallafa.
  • Rashin halarta mai yawa. Kusan rabi na mahalarta da aka magance ba su kammala, kuma rukuni PP ya ƙunshi mutane 30 kawai.
  • Girman samfurin bincike ba tare da ƙididdigar ƙarfin gwaji ba, kuma ba a yi daidaiton gwaje‑gwaje da yawa ba.
  • Lokacin bibiyar gajere: makonni 8 bayan magani na ƙarshe, don haka ba a san ɗorewa ba.
  • Mafi yawa mata, don haka faɗaɗa zuwa maza ba shi da ƙarfi.
  • Kwatanta kai tsaye. Masu bincike sun kwatanta sakamakon da gwaje‑gwajen cryolipolysis (misali, 264.8 mL a makonni 12 a guda ɗaya da 39.6 mL a watanni 2 a wani) kuma suka ce sakamakon CBL‑514 “ya dace da wanda aka samu da liposuction.” Wannan ra'ayi ne na masu rubutu; hanyoyin daban‑daban ne, ba a yi gwaji kai tsaye ba.
  • Laxity na fata an lura da shi ne daga hotunan bayan magani, ba a auna a matsayin maƙasudin hukuma ba.
  • Matsayin bincike. Ba a amince da shi ba, kuma babu tsarin allura da mutum zai yi da kansa.

Bincika jerin CBL-514

Gabaɗaya

A wannan gwajin mataki na 2, CBL‑514 ya haifar da raguwar kitse da aka auna ta ultrasound a yankin ciki, yayin da matsakaicin nauyin jiki ya tsaya ba tare da canji ba idan aka kwatanta da saline. Hanyar ta samo asali ne daga gwajin ba‑na‑mutane na kamfanin wanda ba a wallafa ba. Shaidar da ake da ita ƙanana ce, tana da hannu daga mai tallafa, single‑blind, gajere, kuma adadin mahalarta da suka kammala ya yi ƙasa. Alamar tana nuna alamar da ke da ɗan alkawari, amma tana buƙatar ƙarin gwaje‑gwaje masu girma, tsawon lokaci, da ƙirar blind mafi ƙarfi, ba wani sakamako da aka riga aka yanke hukunci ba.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Ta yaya CBL‑514 ke aiki? Ilimin kimiyya

BY DR. SYNAPSE ·

CBL‑514 ba a nuna shi a matsayin maganin narkewar ko kona kitse ba. Da'awar da ake yi ita ce yana hanawa kinase DYRK1b aiki sannan ya tilastawa ƙwayoyin kitse shiga apoptosis ta hanyar caspase‑3 da Bax/Bcl‑2. Hujjar wannan zaɓi ta samo asali ne daga rahotannin kamfanin da ba a wallafa ba a takardun Phase 2a da Phase 2, kuma ba a fayyace takamaiman tsarin sinadarin ba. Gwajin Phase 2 na 2025 ya auna girman kitse da ultrasound, hotuna, da aminci, ba tare da ƙarin bayanai kamar biopsi ko caspase ba. Wannan labarin na nuni da bambanci tsakanin tunanin sel da abin da aka auna a ɗan adam, ciki har da yawan mutuwar mahalarta da tsarin single‑blind.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Shin CBL‑514 na ƙona mai ainihi? Ga abin da muka sani

BY HELIX WARD ·

Binciken mataki na biyu da aka gudanar a 2025 kan CBL‑514 bai nufin rage nauyin jiki ba; an duba ko alluran da aka yi a ƙirji za su iya rage aƙalla mililita 150 na kitse a ƙarƙashin fata ta hanyar ultrasound. Bayan makonni 8, kashi 69.6 % (16/23) na masu karɓar CBL‑514 sun cimma wannan ragi, yayin da babu ɗaya a rukunin placebo. Duk da haka, matsakaicin nauyin jiki bai ragu ba (ƙara 0.02 kg) kuma kusan rabi na mahalarta ba su kammala binciken ba. Martani a wurin allura ya kasance gama‑gari, ciki har da ƙura a fata a 71.4 % da zafi mai tsanani a 18.4 %. Wannan shine abin da binciken ya nuna da abin da bai nuna ba.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?

BY DR. SYNAPSE ·

Gwaje‑gwajen CBL‑514 su ne gwaje‑gwajen allura da ke binciken tasirin wannan magani, inda adadin 600 mg ke nufin iyakar adadin da ake amfani da shi a kowanne magani a gwaji, ba adadin da za a ci ba. Wannan makala ta bi takaitaccen binciken Phase 2a don tantance ƙimomi (1.2, 1.6, 2.0 mg/cm² a kan 150 cm², n=43, buɗe‑label) kuma ta fayyace asalin adadin 24.96 % da aka ambata. Sannan ta duba Phase 2 da aka gudanar da placebo, inda aka ci gaba da ƙimar 2.0 mg/cm² amma an ninka yanki zuwa 300 cm² tare da iyaka ta 600 mg. Za ku ga dalilin da yasa adadin mg ba za a iya kwatanta su tsakanin gwaje‑gwajen ba, abin da aka rubuta game da tsaro, da kuma dalilin da ya sanya har yanzu ba a amince da shi ba ko ba da shawara ba.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Allurar rage kitsen CBL‑514: Menene kimiyya ke cewa?

BY DR. SYNAPSE ·

CBL‑514 ta wuce gwajin mataki na biyu da aka sarrafa placebo a mujallar *Aesthetic Surgery Journal*, inda marubuta suka ce ta cika manyan manufofin da aka saita. Sai dai wannan bitar na nuna dalilan da ya sa dole a duba ƙirar gwajin sosai: an yi amfani da blind guda ɗaya, masu bincike da mai tallafa ba su da ɓoye, kuma mai tallafa ya shiga ƙirƙira, tantancewa da rubuta sakamakon. Daga cikin mahalarta 75 da aka ba da magani, kawai 38 suka kammala, kuma ƙungiyar da aka yi nazari a kai ta ƙunshi mutane 30 kacal. An dakatar da bibiyar bayan makonni 8, kuma samfurin ya fi yawa mata da fararen fata. Wannan labarin zai fayyace abin da gwajin zai iya tabbatarwa, abin da ba zai iya ba, da dalilin da ya sa ba za a ɗauke shi a matsayin shawara ta likita ko hujja da aka amince da ita ba.

This page is available in